New Gerteis Roller Compactors: Rottendorf Pharma Invests Millions in State-of-the-Art Technology
Production Facilities in Ennigerloh Expanded
24.02.2026, Ennigerloh. Rottendorf Pharma has commissioned a new dry granulation system from Swiss manufacturer Gerteis Maschinen + Processengineering AG at its Ennigerloh site. A second system will be installed later this year. With this investment, the company is committing several million euros to expanding and modernizing its production facilities.
Dry granulation is a key process in the manufacture of solid oral dosage forms and is particularly used for moisture-sensitive or difficult-to-granulate active pharmaceutical ingredients (APIs). By adding this new system, Rottendorf Pharma is strategically expanding its dry granulation capacity and further strengthening its technical capabilities in this production area. Compared to conventional wet granulation, dry granulation is characterized by a simpler process, greater process stability, and lower energy consumption.
“We operate a broad and versatile technology park that enables us to offer our customers different process options for the optimal tableting of their products”, says Erich Scheibner, Managing Director at Rottendorf Pharma. “We handle the APIs entrusted to us with great responsibility and develop efficient, stable manufacturing processes—high-performance equipment from established market leaders is a key foundation for this.”
The new Gerteis system enables precise control of compaction force, roll gap, and additional process parameters. This ensures consistent granule quality—an essential prerequisite for stable tableting processes and reproducible product quality. The systems comply with current GMP requirements and are designed for flexible use across a wide range of products and projects. Scalability from development scale to commercial manufacturing supports the efficient transfer of projects into full-scale production.
“With this investment, we are expanding our dry granulation capacity and modernizing the technical infrastructure at our Ennigerloh site”, explains Marco Niemann, Managing Director of Rottendorf Pharma. “This creates additional production capabilities and ensures the long-term performance of this area.”
“We are delighted that Rottendorf Pharma has chosen Gerteis systems for this investment. This marks a new chapter in the decades-long collaboration between our companies. We greatly value the professional and pleasant exchange with our colleagues at Rottendorf Pharma”, says Michael Hanisch, Senior Project Engineer at Gerteis Maschinen + Processengineering AG.
With the planned installation of the second dry granulation system, available production capacity will be further increased. The investment is part of the company’s ongoing development of its technical infrastructure at the Ennigerloh site.
Dry granulation is a key process in the manufacture of solid oral dosage forms and is used for moisture-sensitive or difficult-to-granulate active pharmaceutical ingredients. Photo: Rottendorf Pharma